[Federal Register Volume 59, Number 162 (Tuesday, August 23, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-20825]


[[Page Unknown]]

[Federal Register: August 23, 1994]


_______________________________________________________________________

Part VI





Department of Health and Human Services





_______________________________________________________________________



National Institutes of Health



_______________________________________________________________________



Recombinant DNA Advisory Committee Meeting; Recombinant DNA Research: 
Proposed Actions Under the Guidelines; Notices
DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

 

Recombinant DNA Advisory Committee; Notice of Meeting

    Pursuant to Public Law 92-463, notice is hereby given of a meeting 
of the Recombinant DNA Advisory Committee on September 12-13, 1994. The 
meeting will be held at the National Institutes of Health, Building 
31C, 6th Floor, Conference Room 6, 9000 Rockville Pike, Bethesda, 
Maryland 20892, starting on September 12, 1994, at approximately 9 
a.m., and will recess at approximately 6 p.m. The meeting will 
reconvene on September 13, 1994, at approximately 8:30 a.m. and will 
adjourn at approximately 5 p.m. The meeting will be open to the public 
to discuss Proposed Actions under the NIH Guidelines for Research 
Involving Recombinant DNA Molecules (59 FR 34496) and other matters to 
be considered by the Committee. The Proposed Actions to be discussed 
will follow this notice of meeting. Attendance by the public will be 
limited to space available. Members of the public wishing to speak at 
this meeting may be given such opportunity at the discretion of the 
Chair.
    In accordance with the provision set forth in sec. 552b(c)(4), 
Title 5, U.S.C. and sec. 10(d) of Pub. L. 92-463, the meeting will be 
closed to the public on September 12 from 5 p.m., to approximately 6 
p.m., for the review, discussion, and evaluation of proprietary 
information which is a part of a human gene therapy research proposal. 
The proposal and the discussion could reveal confidential trade secrets 
or commercial property such as patentable material.
    Dr. Nelson A. Wivel, Director, Office of Recombinant DNA 
Activities, National Institutes of Health, Building 31, Room 4B11, 
Bethesda, Maryland 20892, Phone (301) 496-9838, FAX (301) 496-9839, 
will provide materials to be discussed at this meeting, roster of 
committee members, and substantive program information. Individuals who 
plan to attend and need special assistance, such as sign language 
interpretation or other reasonable accommodations, should contact Dr. 
Wivel in advance of the meeting. A summary of the meeting will be 
available at a later date.
    OMB's ``Mandatory Information Requirements for Federal Assistance 
Program Announcements'' (45 FR 39592, June 11, 1980) requires a 
statement concerning the official government programs contained in the 
Catalog of Federal Domestic Assistance. Normally NIH lists in its 
announcements the number and title of affected individual programs for 
the guidance of the public. Because the guidance in this notice covers 
not only virtually every NIH program but also essentially every Federal 
research program in which DNA recombinant molecule techniques could be 
used, it has been determined not to be cost effective or in the public 
interest to attempt to list these programs. Such a list would likely 
require several additional pages. In addition, NIH could not be certain 
that every Federal program would be included as many Federal agencies, 
as well as private organizations, both national and international, have 
elected to follow the NIH Guidelines. In lieu of the individual program 
listing, NIH invites readers to direct questions to the information 
address above about whether individual programs listed in the Catalog 
of Federal Domestic Assistance are affected.

    Dated: August 3, 1994.
Susan K. Feldman,
Committee Management Officer, NIH.
[FR Doc. 94-20825 Filed 8-22-94; 8:45 am]
BILLING CODE 4141-01-M